IONS Stock Price Today (July 2026) — IONS Analysis & Key Metrics 2026-07-17
IONS (IONS) is trading at $54.39, down 0.48% today (as of July 2026). The stock continues to show pressure below major moving averages, attracting attention from investors looking for Software growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $105.91 (94.7% upside).
- Volatility remains elevated (104.03% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (87.00% YoY) alongside significant competitive pressures.
IONS Stock Analysis: Key Metrics & Valuation (July 2026)
Concise, actionable data for investors
IONS - Historical Price & Volume
Market Cap
Enterprise Value: $14.15B
P/E Ratio
Forward P/E: -134.41
Revenue Growth
Year over Year
Analyst Target
+94.7% upside potential
Key Investor Questions About IONS
What investors need to know before buying
Based on current market data, IONS presents a oversold technical setup with caution warranted fundamentals.
- Technicals say: Oversold (RSI 19.53)
- Fundamentals say: Caution warranted (high leverage concerns)
IONS's growth trajectory depends on its ability to expand within the Software sector while managing margin pressures.
- Future growth will depend on performance in core Software operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for IONS investors include debt exposure and competitive dynamics in the Software industry.
- $2.61B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Software.
52-Week Trading Range
Over the past year, IONS stock traded between $40.03 and $86.74—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 104.03% annualized volatility and β=0.66, the stock exhibits low sensitivity to market moves—making IONS suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Cathie Wood Just Bet Big on This Biotech Stock
Ionis Pharmaceuticals' shares are down more than 27% so far this year. What does Cathie Wood see that others are missing?
Biogen Slumps As Alzheimer's Study Leaves 'More Questions Than Answers'
Biogen and Ionis said Tuesday their tau-targeting Alzheimer's treatment slowed cognitive decline by 26% over the course of 18 months.
Morgan Stanley Raises its Price Target on Alnylam (ALNY)
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is one of the 10 Best Growth Stocks With Highest Upside Potential. On July 10, 2026, Morgan Stanley raised the firm’s price target on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to $400 from $370 and kept an Equal Weight rating on the shares. On July 9, Raymond James raised the firm’s price target […]
Ionis Begins Dosing in Phase I/II Dravet Syndrome Study
IONS doses first patient in the phase I/II ASCEND study of ION337, marking a key step in developing a potential disease-modifying treatment for Dravet syndrome.
Biogen Stock Is Upgraded to Buy Ahead of Key Alzheimer’s Drug Study Details
Biogen stock receives a bullish upgrade based on expectations the market will cheer the company’s detailed data on its experimental Alzheimer’s drug.
The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions
Wainua missed its Phase 3 endpoint, hitting Ionis Pharmaceuticals hard while AstraZeneca absorbed the blow easily, boosting rivals BridgeBio, Pfizer and Alnylam Pharmaceuticals.
Can Biogen Convince Skeptics That Cutting a Rogue Protein Slows Alzheimer’s?
Biogen will present detailed Phase 2 study data for its experimental Alzheimer’s drug diranersen at a conference in London.
Panic grips Ionis Pharmaceuticals investors amid bad news spree
A single failed trial can undo years of work in one trading session, and Ionis Pharmaceuticals (IONS) just went through both consecutively. Ionis Pharmaceuticals lost nearly a quarter of its value on July 9 after its heart drug Wainua failed to meet the primary goal of a late-stage trial. The ...
Is Alnylam Pharmaceuticals (ALNY) Cheap As Rival Trial Failure Shifts ATTR CM Expectations?
Alnylam Pharmaceuticals (ALNY) has drawn fresh attention after shares moved sharply higher, helped by the late stage failure of a competing ATTR cardiomyopathy therapy from AstraZeneca and Ionis Pharmaceuticals, as well as recent collaboration updates. See our latest analysis for Alnylam Pharmaceuticals. Even after the recent surge following competitor trial setbacks and collaboration news, Alnylam Pharmaceuticals’ 1-day share price return declined 4.49%, capping a year to date share price...
Ionis Pharmaceuticals Drops Another 9% as Bad News Piles Up
A Phase 3 trial failure has erased a year of gains for Ionis Pharmaceuticals in just days, and the ripple effects are rattling rivals across the RNA and rare-disease biotech space with more catalysts still ahead.
Frequently Asked Questions
Common investor questions about IONS
IONS (IONS) is currently trading at $54.39. The RSI (14-day) is at 19.5, indicating oversold territory (potentially undervalued). Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $105.91 implies 94.7% upside from current levels. Volatility is high at 104.0% annualized, meaning significant price swings are common. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for IONS (IONS): The trailing P/E ratio is -27.06, which is below the market average of ~20-22, suggesting the stock may be undervalued relative to peers. The forward P/E is -134.41, lower than the trailing P/E, suggesting analysts expect earnings improvement. Price-to-Book is 18.36. Price-to-Sales is 8.49. Valuation should be compared to Software industry peers for context, as different sectors trade at different multiples.
Based on 23 analysts covering IONS, the consensus price target is $105.91. This represents a 94.7% upside from the current price of $54.39. The range spans from a low target of $75.00 to a high target of $130.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
IONS (IONS) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for IONS (IONS) investors include: 1. High volatility (104.0% annualized)—the stock can experience significant daily price swings. 2. Elevated debt levels (D/E ratio of 531.05) which could pressure margins in a rising rate environment. 3. Elevated short interest (14.3% of float) suggests significant bearish sentiment. 4. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 5. Software sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is IONS's (IONS) current debt and financial health profile: Total debt stands at $2.61B. The debt-to-equity ratio is 531.05, which is high and could pose financial risk if earnings decline or borrowing costs increase. The current ratio is 4.10, indicating strong short-term liquidity. The quick ratio is 2.86. The company holds $1.98B in cash and equivalents. Free cash flow is negative at $-807,796,352, which could limit the company's ability to manage debt obligations.